US health regulator approves anti-anxiety device from Belfast-based Neurovalens

Healthtech firm received FDA clearance in October for an anti-insomnia device and has approvals pending for the treatment of PTSD and obesity

Dr. Jason McKeown, Neurovalens CEO, said the FDA approval for Modius Stress represented the “next meaningful step” for the firm’s growth in the US. Picture: Neurovalens